RECEPTOR.AI

company

About

RECEPTOR.AI - drug discovery for precision medecine

  • London,England,United Kingdom
  • 11 - 50

Details

Last Funding Type
Grant
Industries
Artificial Intelligence,Biotechnology,Health Care,Machine Learning,Medical,Pharmaceutical
Founded date
Feb 1, 2021
Number Of Employee
11 - 50
Operating Status
Active
Legal Name
RECEPTOR.AI

Receptor.AI is committed to pushing the boundaries of precision medicine by developing a pipeline of novel small molecules that possess ultimate selectivity in targeting highly similar disease-related proteins such as homologs, mutants, isoforms, and allele variations.

Our proprietary five-level selectivity assessment engine is designed to laser-focus on protein variants specific to particular human populations, organs, tissues and tumour types, ensuring precise alignment with patient profiles.

Receptor.AI platform combines experimental structure determination techniques and AI-augmented medicinal chemistry, unlocking allosteric and cryptic binding pockets and unravelling protein conformational flexibility, making it possible to discriminate between otherwise indistinguishable targets and off-targets.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
RECEPTOR.AI has raised a total of — in funding over 2 rounds. Their latest funding was raised on Dec 1, 2022 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 1, 2022 Grant 1 Campus Detail

Investors

Number of Lead Investors
Number of Investors
1
1
RECEPTOR.AI is funded by 1 investors. Campus are the most recent investors.
Investor Name Lead Investor Funding Round
Campus Yes Grant

Employee Profiles

Number of Employee Profiles
3
RECEPTOR.AI has 3 current employee profiles, including Executive Alan Nafiiev
Executive
Executive
Executive